Search results
...and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the...
CBS 47 Fresno· 1 week agoThe poster will be presented at the American Society for Apheresis (ASFA) 2024 Annual Meeting, taking place April 17-19, 2024, in Las Vegas, Nevada.
Yellow Nail Syndrome: What to Know
Verywell Health via Yahoo News· 1 week agoThis article covers everything you need to know about yellow toenails and fingernails, including causes, symptoms, treatment, and prevention. Pawel...
Xpovio: Mild to serious side effects and how to manage them
Medical News Today· 7 days agoXpovio, which is used to treat multiple myeloma, can cause side effects. Learn about its more...
MC Lyte Using Her Platform To Bring Awareness To This Cancer That Disproportionately Impacts The...
Blavity via Yahoo News· 2 weeks agoMC Lyte is a legend and hip-hop pioneer whose career spans decades, and now she’s getting involved...
Advice From Harvard Health Publishing And 3 More Doctors: What Can Trigger Epilepsy?
MSN News· 1 week agoAnswered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of...
Artificial Sweetener Now Classified as ‘Possible Carcinogen'
Mercola· 19 hours agoThe artificial sweetener aspartame is primarily made up of aspartic acid and phenylalanine. The phenylalanine has been synthetically modified to carry a methyl group, which provides most of ...
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society...
Morningstar· 9 hours ago– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD